Mohammed Waseem A, Ajin P Kurian, Dhanapal Y
email@example.com , firstname.lastname@example.org , email@example.com
Mohammed Waseem A1*, Ajin P Kurian1, Dhanapal Y2
1Department of Pharmaceutics, Sri Ramakrishna Institute of Paramedical Science, Coimbatore – 04.
2Department of Pharmaceutical Analysis PSG College of Pharmacy, Coimbatore – 04.
Volume - 11,
Issue - 2,
Year - 2021
Objective: The purpose of this study was to develop salmeterol, fluticasone nano-lipid carriers to estimate as potentials of oral delivery system for poorly water soluble drugs. Nano-lipid carriers applied to chronomodulated pulsatile drug delivery system maintain the concentration level by releasing the drug at predetermined time interval throughout the management of asthma. Method: The particle size analysis revealed that all the formulations were within the nanometer range of 150.0±2.4nm. Percentage of entrapment efficiency and drug loading were found to be 69.5±4.4 - 85.3±1.3 and 9.358±2.2-10.45±8.1, respectively. The SLM-FCN nano-lipid carrier’s optimized formulation showed spherical morphology with smooth surface under the transmission electron microscope (TEM), the crystalline characterization of drug in NLC was investigated by X-ray diffraction and differential scanning calorimetric (DSC). The ex-vivo permeation study showed many folds increment in the SLM-FCN NLCs compared to powder SLM-FCN 96.0±2.55 and pulsing plugs in-vivo drug released effectively in pre-determine time intervals. Conclusion: The progression concludes that chronomodulated programming pulsatile release was achieved with modified pulsing bilayerd plugged of salmeterol, fluticasone propionate NLCs, formulation remarkably improved oral bioavailability. we promise that finding in this investigations suggest practicability of the dosage form system can be taken after at bedtime then it will be delivered in the early morning which maintains the drug concentration throughout to control asthma.
Cite this article:
Mohammed Waseem A, Ajin P Kurian, Dhanapal Y. Chronomodulated Drug Delivery System of Salmeterol Fluticasone Nlcs Loaded Tablets: Preparation, Characterization, Stability and Drug Release Studies for Management of Asthma. Asian Journal of Research in Pharmaceutical Sciences. 2021; 11(2):95-2. doi: 10.52711/2231-5659.2021-11-2-1
Mohammed Waseem A, Ajin P Kurian, Dhanapal Y. Chronomodulated Drug Delivery System of Salmeterol Fluticasone Nlcs Loaded Tablets: Preparation, Characterization, Stability and Drug Release Studies for Management of Asthma. Asian Journal of Research in Pharmaceutical Sciences. 2021; 11(2):95-2. doi: 10.52711/2231-5659.2021-11-2-1 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2021-11-2-1
1. Anolik R. J Asthma Allergy. 2010 Aug 10; 3: 87-99. Epub 2010 Aug 10.
2. Suthar M, Pulsatile Drug Delivery: A Review, IJPRBS, 2012, 1(1), 1-15.
3. K. Surendra Kumar, M Rama Kotaiah, M Prasada Rao, Formulation and evaluation of pulsatile drug delivery system of metoprolol tartrate, International Journal of Pharmaceutical Research and Bio-Science, 2013, 2(5), 246-257.
4. Haiping Zhang and Jianfang Xu (2016) Enhanced oral bioavailability of salmeterol by loaded PLGA microspheres: preparation, in vitro, and in vivo evaluation, Drug Delivery, 23:1, 248-253, DOI: 10.3109/10717544.2014.909909.
5. Emanuela Fabiola Craparo, Maria Ferraro, Elisabetta Pace, Maria Luisa Bondì, Gaetano Giammona, Gennara Cavallaro Nanomaterials (Basel) 2017 Aug; 7(8): 222. Published online 2017 Aug 13. doi: 10.3390/nano7080222.
6. Beck-Broichsitter M1, Gauss J, Gessler T, Seeger W, Kissel T, Schmehl T, Pulmonary targeting with biodegradable salmeterol-loaded nanoparticles J Aerosol Med Pulm Drug Deliv. 2010 Feb;23(1):47-57. doi: 10.1089/jamp.2009.0759
7. Nashwa El-Gendy,1,3 Warangkana Pornputtapitak,1 and Cory Berkland1,2,* Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols, Eur J Pharm Sci. 2011 Nov 20; 44(4): 522-533. doi: 10.1016/j.ejps.2011.09.014.
8. Vijaykumar Sutariya, Shannon J. Kelly, Robert G. Weigel, Jared Tur, Kathleen Halasz, Nirmal S. Sharma, Srinivas M. Tipparaju. (2019) Nanoparticle drug delivery characterization for fluticasone propionate and in vitro testing. Canadian Journal of Physiology and Pharmacology 97:7, pages 675-684.
9. Deepak Sharma,1 Gurmeet Singh,2 Dinesh Kumar,3 and Mankaran Singh4 Formulation Development and Evaluation of Fast Disintegrating Tablets of Salmeterol Sulphate, Cetirizine Hydrochloride in Combined Pharmaceutical Dosage Form: A New Era in Novel Drug Delivery for Pediatrics and Geriatrics Journal of Drug Delivery Volume 2015,http://dx.doi.org/10.1155/2015/640529.
10. Nanjwade BK, Udhani R, Popat J, Nanjwade VK, Thakare SA (2011) Development and Characterization Salmeterol Sulphate Mouth Disintegrating Tablet. J Chem Eng Process Technol 2:105. doi:10.4172/2157-7048.1000105
11. Damle M and Choudhari S: Development and validation of stability indicating HPLC method for estimation of Salmeterol xinafoate. Int J Pharm Sci and Res 2019; 10(4): 1865-69. doi: 10.13040/IJPSR.0975-8232.10(4).1865-69.
12. COUTO, A.R.S.; CARDOSO, D.E.; CABRAL-MARQUES, H.M. Validation of an HPLC Analytical Method for the Quantitative/Qualitative Determination of Fluticasone Propionate in Inhalation Particles on Several Matrices. Sci. Pharm. 2014, 82, 787-798 https://doi.org/10.3797/scipharm.1404-11.
13. Mukta Paranjpe, Christel Müller-Goymann. (2014) Nanoparticle-Mediated Pulmonary Drug Delivery: A Review. International Journal of Molecular Sciences 15:4, pages 5852-5873.
14. Akmese, B., Sanli, S., Sanli, N. et al. A validated RP-LC method for salmeterol and fluticasone in their binary mixtures and their stress degradation behavior under ICH-recommended stress conditions. J Anal Chem 69, 563–573 (2014). https://doi.org/10.1134/S1061934814060021.
15. Price, D., Small, I., Haughney, J. et al. Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients. Prim Care Respir J 22, 439–448 (2013).
16. Garg, Muneesh et al. “Bioequivalence of Two Formulations of Salmeterol Xinafoate/Fluticasone Propionate HFA pMDI in Healthy Volunteers.” (2017).
17. El-Gendy, Nashwa et al. “Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols.” European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences vol. 44,4 (2011): 522-33. doi:10.1016/j.ejps.2011.09.014.
18. Daley-Yates PT, Mehta R, Chan RH, Despa SX, Louey MD. J Aerosol Med Pulm Drug Deliv. 2014 Aug; 27(4):279-89. Epub 2013 Sep 28.